Discovery of a new class of non-imidazole oxazoline-based histamine H 3 receptor (H3R) inverse agonists

ChemMedChem

Volumn 4, Issue 7, 2009, Pages 1063-1068

  Célanire, Sylvain ^a,c   Wijtmans, Maikel ^b   Christophe, Bernard ^a   Collart, Philippe ^a   De Esch, Iwan ^b   Dassesse, Donald ^a   Delaunoy, Christel ^a   Denonne, Frédéric ^a   Durieu, Véronique ^a   Gelens, Edith ^b   Gillard, Michel ^a   Lallemand, Bénédicte ^a   Lamberty, Yves ^a   Lebon, Florence ^a   Nicolas, Jean Marie ^a   Quéré, Luc ^a   Snip, Erwin ^b   Vanbellinghen, Alain ^a   Van Houtvin, Nathalie ^a   Verbois, Valérie ^a   Timmerman, Henk ^b   Talaga, Patrice ^a   Leurs, Rob ^b   Provins, Laurent ^a   more..

^a UCB PHARMA   (Belgium)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c ADDEX PHARMACEUTICALS   (Switzerland)

Author keywords

Cognitive disorders; Druglike properties; Histamine H3 receptors; Oxazolines; Structure activity relationships

Indexed keywords

2 METHYLPYRROLIDINE; 3 DIMETHYLAMINOPYRROLIDINE; 3,5 DIMETHYLPIPERIDINE; CIPROXIFAN; HISTAMINE H3 RECEPTOR; N ISOPROPYLPIPERAZINE; OXAZOLINE DERIVATIVE; PIPERIDINE; THIOPERAMIDE; TRANS 2,6 DIMETHYLPYRROLIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CACO-2 CELLS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; DRUG INVERSE AGONISM; HISTAMINE H3 ANTAGONISTS; HUMANS; IMIDAZOLES; MICE; OXAZOLES; PREFRONTAL CORTEX; RATS; RATS, WISTAR; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67749099766     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900055     Document Type: Article

References (23)

1. J.-M. Arrang, M. Garbarg, J.-C. Schwartz, Nature 1983, 302, 832-837.
2. J.-M. Arrang, S. Morisset, F. Gbahou, Trends Pharmacol. Sci. 2007, 28, 350-357.
3. a) S. Célanire, F. Lebon, H. Stark in The third histamine receptor: selective ligands as potential therapeutic agents in CNS disorders (Ed.: D. S. Vohora), Taylor & Francis, CRC Press, Boca Raton, 2008, 103-165 and references therein;
4. b) K. Sander, T. Kottke, H. Stark, Biol. Pharm. Bull. 2008, 31, 2163-2181;
5. c) M. Wijtmans, R. Leurs, I. de Esch, Expert Opin. Invest. Drugs 2007, 16, 967-985;
6. d) S. Célanire, M. Wijtmans, P. Talaga, R. Leurs, I. J. P. de Esch, Drug Discovery Today 2005, 10, 1613-1627;
7. e) R. Leurs, R. A. Bakker, H. Timmerman, I. J. P. de Esch, Nat. Rev. Drug Discovery 2005, 4, 107-120.
8. E. Schlicker, B. Malinowska, M. Kathmann, M. Gothert, Fundam. Clin. Pharmacol. 1994, 8, 128-137.
9. T. A. Esbenshade, K. E. Browman, R. S. Bitner, M. Strakhova, M. D. Cowart, J. D. Brioni, Br. J. Pharmacol. 2008, 154, 1166-1181.
10. a) J.-M. Arrang, Int. Rev. Neurobiol. 2007, 78, 247-287;
11. b) E. Southam, J. Cilia, J. E. Garlton, M. L. Woolley, L. P. Lacroix, C. A. Jennings, J. E. Cluderay, C. Reavill, C. Rourke, D. M. Wilson, L. A. Dawson, A. D. Medhurst, D. N. C. Jones, Psychopharmacology 2009, 201, 483-494.
12. a) P. Bonaventure, M. Letavic, C. Dugovic, S. Wilson, L. Aluisio, C. Pudiak, B. Lord, C. Mazur, F. Kamme, S. Nishino, N. Carruthers, T. Lovenberg, Biochem. Pharmacol. 2007, 73, 1084-1096;
13. b) J.-S. Lin, Y. Dauvilliers, I. Arnulf, H. Bastuji, C. Anaclet, R. Parmentier, L. Kocher, M. Yanagisawa, P. Lehert, X. Ligneau, D. Perrin, P. Robert, M. Roux, J.-M. Lecomte, J.-C. Schwartz, Neurobiol. Dis. 2008, 30, 74-83.
14. S. J. Medhurst, S. D. Collins, A. Billington, S. Bingham, R. G. Dalziel, A. Brass, J. C. Roberts, A. D. Medhurst, I. P. Chessell, Pain 2008, 138, 61-69.
15. M. Wijtmans, S. Célanire, E. Snip, M. R. Gillard, E. Gelens, P. P. Collart, B. J. Venhuis, B. Christophe, S. Hulscher, H. van der Goot, F. Lebon, H. Timmerman, R. A. Bakker, B. I. L. F. Lallemand, R. Leurs, P. E. Talaga, I. J. P. de Esch, J. Med. Chem. 2008, 51, 2944-2953.
16. S. Célanire, P. Talaga, R. Leurs, F. Denonne, H. Timmerman, F. Lebon, PCT Int. Appl., 2006, WO2006103057.
17. T. R. Miller, J. L. Baranowski, B. R. Estvander, D. G. Witte, T. L. Carr, A. M. Manelli, K. M. Krueger, M. D. Cowart, J. D. Brioni, T. A. Esbenshade, Assay Drug Dev. Technol. 2008, 6, 339-349.
18. G. J. Menkveld, H. Timmerman, Eur. J. Pharmacol. 1990, 186, 343-347.
19. G. Bongers, K. M. Krueger, T. R. Miller, J. L. Baranowski, B. R. Estvander, D. G. Witte, M. I. Strakhova, P. van Meer, R. A. Bakker, M. D. Cowart, A. A. Hancock, T. A. Esbenshade, R. Leurs, J. Pharmacol. Exp. Ther. 2007, 323, 888-898.
20. 3-receptor inverse agonists but not the neutral antagonist GT-2331 modulate cortical cholinergic system in the rat: a microdialysis study" Society for Neuroscience abstracts, 435.18, 2004.
21. V. Bertaina-Anglade, E. Enjuanes, D. Morillon, C. Drieu la Rochelle, J. Pharmacol. Toxicol. Methods 2006, 54, 99-105.
22. 2O (2 mL) saturated with octanol then filtrated. This solution (0.5 μL) was added to 0.5 μL of the other phase and sonicated. The samples were then centrifuged for 1 h. Quantification of each phase was performed by HPLC. The distribution coefficient is the logarithm of the ratio between HPLC trace surface areas from the octanol phase over those of the aqueous phase at a given pH.
23. The dextromethorphan O-demethylase assay for CYP2D6 inhibition and the midazolam 1′-hydroxylase assay for CYP3A4 inhibition are described in reference [9].